ABBV - Concert Pharmaceuticals Is Unlikely To Grab A Large Piece Of The Alopecia Areata Drug Market
- There is no cure for alopecia areata and the latter affects as many as 6.8 million people in the U.S. alone.
- Concert is among the several companies developing a drug and it aims to present an NDA submission in early 2023.
- However, I doubt it will be the first to reach the market and also it doesn’t have the marketing budget to compete with companies like Eli Lilly, Pfizer and AbbVie.
For further details see:
Concert Pharmaceuticals Is Unlikely To Grab A Large Piece Of The Alopecia Areata Drug Market